EUVIMEDEUVIMED entdecken
Open Access

Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication

Philip Vutien iD, Nicole J Kim iD, Andrew M Moon iD, Kay M Johnson, Kristin Berry, Pamela K Green, George N Ioannou

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17802 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Philip Vutien und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Coinfection, Hepatitis C. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CSRD VA, HSRD VA, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It is unclear whether the risk of hepatocellular carcinoma (HCC) decreases over time following hepatitis C virus (HCV) eradication.

Aim

To determine if patients who have accrued longer time since sustained virologic response (SVR) have a lower risk of HCC than those with less time since SVR Methods We conducted a retrospective cohort study of all HCV‐infected Veterans Affairs patients who achieved SVR before 1 January 2018 and remained alive without a diagnosis of HCC as of 1 January 2019 ( n = 75,965). We ascertained their baseline characteristics as of 1 January 2019 (time zero), including time accrued since SVR and followed them for the subsequent 12 months for incident HCC. We used multivariable Cox proportional hazards regression to determine the association between time since SVR and HCC risk after adjusting for age, race/ethnicity, sex, diabetes, hypertension, body mass index, alcohol use, Charlson Comorbidity Index, Fibrosis‐4 score, HCV genotype, hepatitis B virus co‐infection and HIV co‐infection.

Results

96.0% were male; mean age was 64.6 years. Among those with cirrhosis ( n = 19,678, 25.9%), compared to patients who had accrued only ≥1 to 2 years since SVR (HCC incidence 2.71/100 person‐years), those who had accrued >2 to 4 years (2.11/100 person‐years, aHR 0.80, 95% CI 0.63–1.01) and >4 to 6 years (1.65/100 person‐years, aHR 0.61, 95% CI 0.41–0.90) had progressively lower HCC risk. However, HCC risk appeared to plateau for those with >6 years since SVR (1.68/100 person‐years, aHR 0.70, 95% CI 0.46–1.07). Among those without cirrhosis, HCC risk was 0.23–0.27/100 person‐years without a significant association between time since SVR and HCC risk.

Conclusions

Among patients with cirrhosis and cured HCV infection, HCC risk declined progressively up to 6 years post‐SVR—although it remained well above thresholds that warrant screening. This suggests that time since SVR can inform HCC surveillance strategies in patients with cured HCV infection and can be incorporated into HCC risk prediction models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsCoinfectionHepatitis CHepatitis C, ChronicHumansMaleMiddle AgedFemaleHepacivirusRisk FactorsRetrospective StudiesAntiviral AgentsLiver CirrhosisSustained Virologic Response

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, University of Washington, Seattle, Washington, USA.
  • Division of Gastroenterology, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA.
  • Division of Gastroenterology and Hepatology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Hospital and Specialty Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA.
  • Division of General Internal Medicine, University of Washington School of Medicine, Seattle, Washington, USA.

ORCID-Profile: Philip Vutien, Nicole J Kim, Andrew M Moon

Förderung

  • CSRD VA
  • HSRD VA
  • NCI NIH HHS
  • American Association for the Study of Liver Diseases
  • Health Services Research and Development

Zitieren

APA

Vutien, P., Kim, N. J., Moon, A. M., Johnson, K. M., Berry, K., Green, P. K., & Ioannou, G. N. (2024). Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17802

Vancouver

Vutien P, Kim NJ, Moon AM, Johnson KM, Berry K, Green PK, et al. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17802

BibTeX
@article{Vutien2024,
  author = {Vutien, Philip and Kim, Nicole J and Moon, Andrew M and Johnson, Kay M and Berry, Kristin and Green, Pamela K and Ioannou, George N},
  title = {Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17802}
}
Kostenlos starten →